52 completed. 52 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 52 | Completed 52 |
Follow Osteoporosis, Postmenopausal: new trials by email Literature Review of Osteoporosis, Postmenopausal trials Research Report on Osteoporosis, Postmenopausal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. Romosozumab - Postmenopausal Osteoporosis | Phase 4 | Completed | Amgen | 100 | 2023-10-30 | 2026-10-21 |
| Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women Risedronate Sodium 35 MG [Actonel], Calcium Vitamin D combination - Postmenopausal Osteoporosis | Phase 4 | Completed | Dong-A ST Co., Ltd. | 149 | 2023-01-03 | 2025-08-24 |
| Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease Denosumab, Alendronate Sodium - Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal | Phase 4 | Completed | Aristotle University Of Thessaloniki | 72 | 2022-12-23 | 2026-07-23 |
| Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Teriparatide, Denosumab - Postmenopausal Osteoporosis | Phase 4 | Completed | Massachusetts General Hospital | 37 | 2019-09-02 | 2023-08-02 |
| Effect of Pitavastatin on Bone Pitavastatin - Osteoporosis, Osteopenia, Hypercholesterolemia | Phase 4 | Completed | Seoul National University Bundang Hospital | 70 | 2019-04-08 | 2024-04-11 |
| MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis Prolia, 60 Mg/mL Subcutaneous Solution, Teriparatide - Postmenopausal Osteoporosis, Diabetes Type 2 | Phase 4 | Completed | Medical University of Vienna | 26 | 2017-03-01 | 2023-01-26 |
| Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis Phase 1 periodontal therapy, Bisphosphonate therapy - Osteoporosis, Postmenopausal, Periodontitis | Phase 4 | Completed | Ondokuz Mayıs University | 43 | 2016-06-30 | 2021-03-11 |
| Preventing Osteoporosis Using Denosumab denosumab, Placebo, Calcium and Vitamin D - Osteoporosis, Postmenopausal, Osteoporosis | Phase 4 | Completed | Susan L. Greenspan | 201 | 2016-06-01 | 2024-09-19 |
| Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) Zoledronic acid, vitamin D, calcium - Osteoporotic Fractures, Osteoporosis, Postmenopausal | Phase 4 | Completed | Susan L. Greenspan | 310 | 2016-01-01 | 2023-09-26 |
| Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation Denosumab, Zoledronic acid - Postmenopausal Osteoporosis | Phase 4 | Completed | 424 General Military Hospital | 57 | 2015-07-01 | 2019-03-11 |
| Denosumab and Teriparatide Study (DATA-HD and DATA-EX) denosumab, teriparatide, Zoledronic acid - Postmenopausal Osteoporosis | Phase 4 | Completed | Massachusetts General Hospital | 76 | 2014-08-01 | 2021-02-09 |
| Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women Bazedoxifene, Calcium/Vit D - Osteoporosis, Postmenopausal | Phase 4 | Completed | Instituto Palacios | 110 | 2013-05-01 | 2015-09-09 |
| Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet - Postmenopausal Osteoporosis | Phase 4 | Completed | Massachusetts General Hospital | 27 | 2013-01-01 | 2017-03-27 |
| Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Denosumab, Zoledronic Acid, Placebo to Denosumab - Post Menopausal Osteoporosis | Phase 4 | Completed | Amgen | 643 | 2012-11-07 | 2020-03-10 |
| VERtebral Fracture Treatment Comparisons in Osteoporotic Women Teriparatide, Risedronate, Placebo - Postmenopausal Osteoporosis | Phase 4 | Completed | Eli Lilly and Company | 1366 | 2012-10-01 | 2019-09-23 |
| Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss Pearlium/EffectiCal, Calcium carbonate/vitamin D3 - Osteoporosis, Postmenopausal | Phase 4 | Completed | University of Alberta | 97 | 2012-07-12 | 2023-05-09 |
| A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus), Calcitriol, Calcium 500 mg - Osteoporosis, Postmenopausal | Phase 4 | Completed | Organon and Co | 219 | 2011-06-19 | 2024-06-20 |
| Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Raloxifene, Strontium ranelate - Postmenopausal Osteoporosis, Compliance | Phase 4 | Completed | University of Valencia | 80 | 2009-09-01 | 2012-09-03 |
| Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women Teriparatide, Zoledronic Acid - Osteoporosis, Post-menopausal | Phase 4 | Completed | Eli Lilly and Company | 69 | 2009-07-01 | 2013-04-04 |
| Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263) alendronate sodium (+) cholecalciferol, Comparator: Alendronate sodium (Fosamax), Comparator: Calcium - Osteoporosis Postmenopausal | Phase 4 | Completed | Organon and Co | 343 | 2008-03-20 | 2024-04-23 |
Showing 20 of 52. Sign in to see all of them.
Osteoporosis (11) · Bone Diseases, Metabolic (6) · Osteoporotic Fractures (2) · Diabetes Mellitus, Type 2 (1) · Fatty Liver (1) · Frailty (1) · Hypercholesterolemia (1) · Liver Cirrhosis (1) · Non-alcoholic Fatty Liver Disease (1) · Patient Compliance (1) · Periodontitis (1) · Sclerosteosis (1) · Spinal Fractures (1)
Bone Diseases (52) · Metabolic Diseases (52) · Musculoskeletal Diseases (52) · Nutritional and Metabolic Diseases (52) · Bone Diseases, Metabolic (46) · Osteoporosis (41) · Fractures, Bone (3) · Wounds and Injuries (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Back Injuries (1) · Behavior (1) · Diabetes Mellitus (1) · Digestive System Diseases (1) · Dyslipidemias (1)
Ibandronic Acid (16) · Teriparatide (12) · Risedronic Acid (9) · Denosumab (8) · Alendronate (6) · Raloxifene Hydrochloride (6) · Calcium (5) · Vitamin D (5) · Zoledronic Acid (5) · Cholecalciferol (3) · strontium ranelate (2) · Calcitriol (1) · Calcium Carbonate (1) · Fumigant 93 (1) · Injections, Subcutaneous (1)
Hoffmann-La Roche (14) · Eli Lilly and Company (10) · Sanofi (6) · Massachusetts General Hospital (3) · Amgen (2) · Charite University, Berlin, Germany (2) · Organon and Co (2) · Susan L. Greenspan (2) · 424 General Military Hospital (1) · Aristotle University Of Thessaloniki (1) · Dong-A ST Co., Ltd. (1) · GlaxoSmithKline (1) · Instituto Palacios (1) · Medical University of Vienna (1) · Ondokuz Mayıs University (1)
United States (25) · Spain (8) · Germany (7) · Belgium (6) · Canada (6) · France (5) · Greece (5) · Mexico (5) · Poland (5) · Czechia (4) · Hungary (4) · Puerto Rico (4) · Australia (3) · Austria (3) · Brazil (3)
Benjamin Leder, MD (2) · Dieter Felsenberg, Prof. Dr. (2) · Susan L Greenspan, MD (2) · Antonio Cano, MD (1) · Antonis Goulas, MD, PhD (1) · Athanasios D Anastasilakis, MD, PhD (1) · Athanasios D Anastasilakis, PhD (1) · Choe Seong Choon (1)
PMID 16018754, PMID 18682511, PMID 18838053, PMID 19584192, PMID 21703900, PMID 24576302, PMID 24719139, PMID 25929192, PMID 25933031, PMID 26367496, PMID 26841258, PMID 29129436, PMID 29329484, PMID 30659410, PMID 31447409, PMID 32157334, PMID 32474650, PMID 33386953, PMID 34231877
2005 (1), R01AG050302 (1), R01AG052123 (1), R01AR073191 (1)